Scotiabank Initiates Coverage On BridgeBio Pharma with Sector Outperform Rating, Announces Price Target of $44

Benzinga · 10/16 14:01
Scotiabank analyst Greg Harrison initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Sector Outperform rating and announces Price Target of $44.